MAWAG
PLRX icon

Mid-American Wealth Advisory Group’s Pliant Therapeutics PLRX Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54
Closed -$63 – 242
2025
Q2 		$63 Buy
+54
New +$76 ﹤0.01% 336

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Mid-American Wealth Advisory Group's PLRX Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 54 shares — an estimated $63 sold.

Mid-American Wealth Advisory Group first reported a position in PLRX in Q2 2025 and held it in 1 quarter. The position peaked at $63 in Q2 2025. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 54 Pliant Therapeutics shares in Q3 2025, an estimated $63.
  • Mid-American Wealth Advisory Group first reported a position in Pliant Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Pliant Therapeutics position peaked at $63 in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.